PliaFX Flo Subtalar Fusion Study
A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada
During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.
This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 초기 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Biraj Bora
- 전화번호: 604-813-0889
- 이메일: biraj.bora@phc.ca
연구 장소
-
-
British Colombia
-
Vancouver, British Colombia, 캐나다, V6Z 1Y6
- St. Paul's Hospital
-
연락하다:
- Biraj Bora
- 전화번호: 604-813-0889
- 이메일: biraj.bora@phc.ca
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- The subject is at least 19 years of age.
- The subject is considered to be skeletally mature.
- The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
- The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
- The patient may undergo a subtalar fusion as part of a triple arthrodesis.
- The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
- The patient consented for either an arthroscopic or open procedure.
- The subject is able to comply with all post-operative evaluations and visits.
- The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery
Exclusion Criteria:
-
The subject has:
- Severe osteoporosis
- Neuromuscular impairment
- Prior infection in the affected joint
-
The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.
-
The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).
-
The subject is renal compromised.
-
The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).
-
The subject is undergoing a revision of a prior subtalar fusion.
-
The subject has had a prior ankle joint fusion.
-
An ankle joint replacement or ankle joint fusion may be performed during the same sitting.
-
The subject has a BMI of > 50 kg/m2.
-
The subject is known to be pregnant, or plans to become pregnant during the study period
-
The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).
-
The subject is unable to provide informed consent.
-
The subject is unable to communicate with the research team.
-
The subject is unable to comply with follow-up.
-
The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry
-
The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 장치 타당성
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: PliaFX Flo Allograft
Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure. |
Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure. |
|
간섭 없음: No Graft
Participant will receive no graft during their Subtalar Arthrodesis procedure. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Bone Bridging Percentage
기간: Enrollment to last Follow-up visit (52 weeks)
|
Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively. |
Enrollment to last Follow-up visit (52 weeks)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Foot and Ankle Measure (FAAM) Questionnaire
기간: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Current Health Assessment Questionnaire
기간: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
기간: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Demographics Questionnaire
기간: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
|
|
Ankle Osteoarthritis Scale
기간: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 1, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
SF-36 Health Survey
기간: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- H26-01617
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .